Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects

Zhou, Zhirui; Yang, Zhaozhi; Yu, Xiaoli; Guo, Xiaomao

doi:10.1002/cam4.1588

Cited by 5 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is intense interest in the discovery of radiosensitizing agents for breast cancer [18] and this study highlights the potential of translation-initiation as another avenue for target discovery.…”

Section: Discussionmentioning

confidence: 98%

The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy

Webb

Davies

Maher

et al. 2020

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy

Webb

Davies

Maher

et al. 2020

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…A great challenge is identifying individuals who have a high risk of recurrence. Genetic testing provides valuable prognostic information for early-stage patients with breast cancer in order to obtain possible prognostic information as part of their treatment regimens [ 9 ]. Gene expression profiles and whole genome sequencing are increasingly being incorporated into the treatment planning process for breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer

Al-Mansouri,

Abdullah,

Ali

et al. 2023

JMedLife

View full text Add to dashboard Cite

HER-2-positive breast cancer is characterized by its aggressive nature, poor prognosis, and reduced overall survival. The emergence of trastuzumab resistance is currently considered a global problem. The immune system plays a pivotal role in tumor progression and development. Cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and other immune checkpoint proteins may be potential prognostic factors and therapeutic targets for breast cancer. This study aimed to determine the correlation between CTLA-4 expression in peripheral blood and insulin-like growth factor-1 (IGF-1) serum levels and their impact on trastuzumab responsiveness in HER-2-positive patients with breast cancer. CTLA-4 expression was analyzed in peripheral blood cells using quantitative PCR, while IGF-1 serum levels were assessed through electrochemiluminescence assays. There was a significant increase in CTLA-4 expression at cycle 9, which continued to increase until it reached 4.6 at cycle 17. High IGF-1 levels were observed in newly diagnosed HER-2 positive patients before trastuzumab therapy, significantly decreasing post-therapy (p=0.001). Co-targeting HER-2 and IGF-1 receptors may reduce the risk of recurrence and improve outcomes. In addition, targeted CTLA-4 molecules may improve patient survival and prevent recurrence.

show abstract

“…H19, an imprinted lncRNA, is one of the first identified lncRNAs 16. Accumulating evidence reveals that the dysregulated H19 acts as the tumorigenic and anti-tumorigenic roles in many tumors, such as bladder cancer,17 breast cancer 18. Huang et al have reported that H19 are associated with cell invasion and metastasis in EC 19.…”

Section: Introductionmentioning

confidence: 99%

<p>Downregulation of H19 decreases the radioresistance in esophageal squamous cell carcinoma cells</p>

Luo¹,

Liu²,

Yao³

et al. 2019

OTT

View full text Add to dashboard Cite

Background: Radiotherapy is one of the most common treatments for esophageal squamous cell carcinoma (ESCC). Radioresistance is a major obstacle that limits the efficacy of radiotherapy. H19 has been considered as a factor affecting radioresistance, whereas the specific mechanism of H19 in ESCC radioresistance remains to be further elucidated. Purpose: The objective of this study was to identify the relationship between H19 and radioresistance. The findings are expected to provide new insights into the treatment of radioresistant ESCC. Methods: The expression levels of H19 in ESCC was analyzed using the online database starBase. The Oncomine database was used to further verify the association between H19 expression and patient age, gender, and tumor stage. The overall survival rates of ESCC patients were analyzed using the KM plotter database. Clonogenic survival was conducted to identify the value of survival fraction. The optical density values were obtained via MTS assays. Cells migration and stemness were observed through Transwell and sphere formation assays. The expression levels of H19, miR-22-3p and WNT1 were analyzed using qPCR. Results: In our study, we firstly screened the H19 according to the online database starBase, and then the Oncomine database and KM plotter database showed that H19 expression was significantly upregulated in the ESCC tissues and associated with poor prognosis. Secondly, an ESCC radioresistant cell line, KYSE150R was established. Clonogenic survival showed that radiation decreased the value of survival fraction. MTS assays suggested that optical density values in KYSE150R cells were significantly higher than that in KYSE150 cells. Transwell and sphere formation assays showed radiation enhanced cell migration and stemness in ESCC cells. In addition, qPCR showed that H19 was upregulated in KYSE150R cells, and survival fraction assays showed that knockdown of H19 decreased the survival fraction values. MTS assays, migration and invasion assays suggested that H19 inhibited cells proliferation, migration and stemness in radioresistant KYSE150 cells. Moreover, qPCR assay showed that miR-22-3p expression levels was downregulated, but WNT1 was upregulated in KYSE150R cells as well as protein levels. Luciferase activity assay further showed that miR-22-3p inhibits the WNT1 expression. Conclusion: Our results demonstrate that H19 knockdown downregulates the WNT1 via upregulating miR-22-3p expression, which leads to the inhibition of cells proliferation, migration and stemness in the radioresistant ESCC cells.

show abstract

Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects

Cited by 5 publications

References 87 publications

The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy

The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy

Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer

<p>Downregulation of H19 decreases the radioresistance in esophageal squamous cell carcinoma cells</p>

Contact Info

Product

Resources

About